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REGULAR ARTICLE
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Key Points

• Acalabrutinib had good
tolerability in patients
with relapsed or refractory CLL who were
intolerant to ibrutinib.
• Acalabrutinib demonstrated a high response
rate (81%) in patients
with relapsed or refractory CLL who were
intolerant to ibrutinib.

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic
lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs)
leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater
selectivity than ibrutinib. We evaluated the safety and eﬃcacy of 100 mg of acalabrutinib
twice daily or 200 mg once daily in patients with CLL who discontinued ibrutinib because
of intolerance as determined by the investigators. Among 33 treated patients (61% men;
median age, 64 years; range, 50-82 years), median duration of prior ibrutinib treatment
was 11.6 months (range, 1-62 months); median time from ibrutinib discontinuation to
acalabrutinib start was 47 days (range, 3-331 days). After a median of 19.0 months (range,
0.2-30.6 months), 23 patients remained on acalabrutinib; 10 had discontinued (progressive
disease, n 5 4; AEs, n 5 3). No acalabrutinib dose reductions occurred. During
acalabrutinib treatment, the most frequent AEs included diarrhea (58%), headache (39%),
and cough (33%). Grade 3/4 AEs occurred in 58%, most commonly neutropenia (12%)
and thrombocytopenia (9%). Of 61 ibrutinib-related AEs associated with intolerance,
72% did not recur and 13% recurred at a lower grade with acalabrutinib. Overall response
rate was 76%, including 1 complete and 19 partial responses and 5 partial responses
with lymphocytosis. Among 25 responders, median duration of response was not reached.
Median progression-free survival (PFS) was not reached; 1-year PFS was 83.4%
(95% conﬁdence interval, 64.5%-92.7%). Acalabrutinib was well tolerated with a high
response rate in patients who were previously intolerant to ibrutinib. This trial was
registered at www.clinicaltrials.gov as #NCT02029443.

Introduction
Chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the West,1 is a mature
B-cell malignancy characterized by proliferation and survival signals associated with chronic active
B-cell receptor (BCR) signaling2 for which Bruton tyrosine kinase (BTK) is critical.3 Understanding
the role of BTK in disease pathogenesis led to the development of ibrutinib, a covalent BTK inhibitor
that improved progression-free survival (PFS) and overall survival (OS) in patients with CLL
compared with conventional therapies.4-6 Despite the efficacy of ibrutinib, many patients with CLL
cannot maintain benefit from BTK inhibition because of the development of treatment-limiting
Submitted 14 December 2018; accepted 8 March 2019. DOI 10.1182/
bloodadvances.2018030007.
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adverse events (AEs). These ibrutinib-related AEs include atrial
fibrillation, arthralgias, rash, diarrhea, and bleeding and have led
to ibrutinib discontinuation in 9% to 14% of patients in clinical
studies6-11 and ;22% of patients in routine clinical practice.12-14
Ibrutinib potently inhibits BTK and leads to inhibition of BCR
signaling.15 Ibrutinib also targets many other cellular processes
through the roles of BTK outside of BCR signaling and the
inhibition of other kinases,15-18 leading to an impact upon normal
processes in T lymphocytes, macrophages, and platelets.19-28
Collectively, these effects of ibrutinib on multiple cellular processes
may influence its AE profile.
Acalabrutinib is a potent, highly selective, covalent BTK inhibitor
with minimal off-target activity.16,17,29 In vitro, acalabrutinib has
greater relative selectivity than ibrutinib for BTK over off-target
kinases such as TEC (25- vs 6.7-fold), epidermal growth factor
receptor (.200- vs 3.5-fold), and interleukin-2–inducible T-cell
kinase (.200- vs 3.3-fold).16 Acalabrutinib showed minimal activity
on nontarget cell types at physiologically relevant concentrations,
including T cells,16,30 natural killer cells,25 and epithelial cell lines.16
Additionally, thrombus formation was not impaired in platelets from
acalabrutinib-treated patients when tested in a humanized mouse
model, but it was impaired in platelets from patients receiving ibrutinib.17
On the basis of the safety and tolerability observed with
acalabrutinib in patients with relapsed or refractory CLL, including
an overall response rate (ORR; response of partial response [PR]
with lymphocytosis [PRL] or better) of 93% and estimated 18-month
PFS of 90%,17,31 we hypothesized that patients with CLL who
discontinued ibrutinib because of treatment-limiting AEs could still
derive clinical benefit from a more selective BTK inhibitor. Here, we
present the safety and efficacy of acalabrutinib treatment in patients
with relapsed or refractory CLL or small lymphocytic lymphoma (SLL)
who had previously discontinued ibrutinib because of intolerance.17,31

Patients and methods
Study design
Patients in this study were an added cohort of the open-label phase
2 dose expansion of a multicenter phase 1/2 study.17,31 The
efficacy and safety of acalabrutinib were evaluated in this cohort
of patients with CLL or SLL who were intolerant to ibrutinib, as
determined by the investigator. Patients were enrolled across
7 major US and UK academic centers. The study was conducted in
accordance with the International Conference on Harmonisation
Guidelines for Good Clinical Practice and the Declaration of
Helsinki. The institutional review board at each site approved the
protocol. All patients provided written informed consent.
The planned acalabrutinib dosage for this cohort was 100 mg twice
daily (n 5 30) and 200 mg once daily (n 5 3). Three patients
originally receiving the 200-mg once-daily dose were later switched
to 100 mg twice daily based on preclinical BTK occupancy studies;
all 3 received #56 days of initial 200-mg once-daily acalabrutinib
treatment. Acalabrutinib was continued until disease progression
or unacceptable toxicity.

Patients
Eligible patients had confirmed CLL or SLL, as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL).32
Patients with ibrutinib intolerance were defined as those who were
1554
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unable to continue the medication because of ibrutinib-related
AEs, as determined by the investigator.4,5 Resolution of these AEs
was not required before initiating acalabrutinib. Patients were not
required to have disease progression before entering this study;
additionally, the initial protocol did not require measurable disease
or an indication for treatment, but it was subsequently modified. All
enrolled patients had detectable CLL. Measurable disease was
defined as $1 lymph node $2 cm, as measured in the longest
diameter. Other eligibility criteria included age $18 years and
Eastern Cooperative Oncology Group performance status #2.
Patients were excluded if they had progressed while receiving
ibrutinib. Additional exclusion criteria included absolute neutrophil
count ,0.75 3 109 /L, platelet count ,50 3 109 /L (unless there
was bone marrow involvement), known CLL central nervous
system disease involvement, and estimated creatinine clearance
,30 mL per minute. Patients with significant cardiovascular disease
(uncontrolled or symptomatic arrhythmias, congestive heart failure,
or myocardial infarction), any class 3 or 4 cardiac disease per New
York Heart Association functional classification, or corrected QT
interval .480 ms were excluded. Patients with prior or concurrent
atrial fibrillation were eligible. Concomitant treatment with warfarin
or equivalent vitamin K antagonists was prohibited; other anticoagulants were permitted.

Objectives
The primary objective was to determine the safety of acalabrutinib
in patients intolerant to ibrutinib, as assessed by frequency,
severity, and attribution of AEs based on the Common Terminology Criteria for Adverse Events (version 4.03). Secondary
objectives included the determination of investigator-assessed
ORR (including PRL), duration of response (DOR), and investigatorassessed PFS. Response was evaluated using the IWCLL
criteria; however, isolated lymphocytosis was not considered to
indicate relapse.32,33 Pharmacodynamic analysis of baseline and
on-study samples and genomic analyses of baseline samples
were exploratory end points.

Study procedures
Each patient had a baseline assessment that included clinical
history, physical examination, laboratory testing, and imaging
studies. Safety assessments were based on the frequency and
severity of AEs, standard clinical laboratory tests, and measurements of vital signs. Prior AEs experienced during ibrutinib
treatment were recorded at study entry. Treatment-emergent
AEs experienced during acalabrutinib treatment were classified as
recurrent AEs if the same AE had been experienced while receiving
ibrutinib. Disease status was assessed at baseline and during
the study using computed tomography, physical examination, and
laboratory tests. Radiologic tumor assessments occurred at the end
of cycles 2, 4, and 6, then every 6 cycles until cycle 36, and every
12 cycles thereafter. Bone marrow biopsy was required for confirmation of a complete response (CR).

Statistical analyses
Descriptive statistics (including means, standard deviations, medians, and ranges for continuous variables and proportions for
discrete variables) were used to summarize data as appropriate.
Safety and efficacy were evaluated in all patients who received $1
dose of study drug. Disease parameters (imaging and laboratory
14 MAY 2019 x VOLUME 3, NUMBER 9

parameters) performed at study entry were used as the baseline for
response assessment. PFS was defined as the time from the first
dose of acalabrutinib to documented disease progression or death
and estimated using Kaplan-Meier methodology; patients without
disease progression or death were censored for PFS at the time of
last follow-up.

Pharmacodynamic analysis
As described previously,17 BTK occupancy (the level of drug
binding to BTK) by acalabrutinib was measured in peripheral
blood mononuclear cells (PBMCs) with the aid of a biotintagged analog probe on day 1 (predose and 4 hours postdose)
and on days 2, 8, and 28 and on day 28 of cycle 6 (predose).
The BTK occupancy was calculated relative to each patient’s
baseline control (day 1 predose). Phosphorylation of BTK on the
tyrosine 223 residue was evaluated in PBMCs stimulated with
goat anti-human immunoglobulin M F(ab9)2 (Southern Biotech)
and hydrogen peroxide using intracellular flow cytometry as
described previously.16,17

Genomic analysis
Exploratory genomic evaluation was conducted on baseline patient
samples. A targeted next-generation sequencing 220-gene panel
(Cancer Genetics Inc) was used to analyze baseline PBMC pellets.
Sequencing variants were called using VarDict from the BAM files
provided by Cancer Genetics Inc34 and then filtered to remove
sequencing artifacts (if novel and present in .40% of samples or

Enrollment

called in a low-sequence complexity region or a repeated region in
the genome), low-quality calls (,5 reads supporting alternative
variants, mean base quality Phred score ,25, or mean mapping
quality score ,10), and germ line single-nucleotide polymorphisms
(removed if allele frequency was .0.0025 vs population singlenucleotide polymorphism databases [1000 Genomes Project
(phase 3) and Broad ExAC]). Additionally, variants with allele
frequency ,5% were filtered.

Data sharing statement
Data underlying the findings described in this manuscript may
be obtained in accordance with the AstraZeneca data sharing
policy.35

Results
Patients
From 11 September 2014 to 24 November 2015, 35 patients with
CLL who were considered ibrutinib intolerant were enrolled and 33
were treated with acalabrutinib; 1 was withdrawn by the investigator
(lack of active disease), and 1 withdrew consent before first dose
(pursued alternate therapy; Figure 1). Median patient age was
64 years (range, 50-82 years); 49% were age $65 years. At baseline,
many patients had high-risk disease: 27% had a Rai stage of III or IV,
31% had bulky lymph nodes, 38% had deletion of chromosome
17(p13.1) [del(17)(p13.1)], 22% had del(11)(q22.3), and 78% had
b2-microglobin .3 mg/L (Table 1).36 Most patients (81%) had
unmutated IGHV, and 52% of patients had baseline cytopenias

Assessed for eligibility (n = 37)

Excluded (n = 2)
• Did not meet inclusion criteria (n = 2)

Enrolled (n = 35)

Allocation
Allocated to treatment (n = 35)
• Received acalabrutinib (n = 33)
• Did not receive acalabrutinib (n = 2; withdrawn
consent, investigator decision)

Follow-Up
Discontinued acalabrutinib (n = 10)
• Progressive disease (n = 4 [Richter transformation, n = 2])
• Adverse event (n = 3 [metastatic endometrial cancer,
hemorrhagic stroke, Aspergillosis infection])
• Physician decision (n = 3 [concurrent hemophilia, increased
BTK resistance, CLL CNS involvement])
Analysis

Figure 1. Patient flow through the study. CNS,

Analyzed (n = 33)

central nervous system.
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(neutropenia in 12% [grade $3, 9%], anemia in 18% [6%], and
thrombocytopenia in 21% [12%]). Patients were heavily pretreated, with a median of 4 prior therapies (range, 2-13 therapies);
20 patients (61%) had received $4 lines of prior systemic therapy.
Median duration of prior ibrutinib treatment was 11.6 months
(range, 1-62 months); median duration from the end of ibrutinib to the
start of acalabrutinib treatment was 47 days (range, 3-331 days).
Thirty patients (91%) had ibrutinib as their most recent prior
treatment. Six patients with detectable CLL were treated based
on investigator and patient discretion without meeting the
conventional indication for treatment per IWCLL 2008 criteria.
The protocol was subsequently amended to require patients to
have a specific indication for treatment per IWCLL criteria. Five
of these 6 patients were dosed and evaluable for efficacy and
were transitioned immediately from ibrutinib to acalabrutinib to
avoid tumor flare that typically occurs with BTK inhibitor therapy
discontinuation.

Table 1. Baseline characteristics of all treated patients (N 5 33)
Characteristic

n or n/N (%)

Age, y
Median

64

Range

50-82

Male sex

20 (61)

ECOG performance status #1

32 (97)

Rai stage III-IV

9 (27)

Bulky disease $5 cm

10/32 (31)

b2-microglobulin .3 mg/L

21/27 (78)

No. of prior therapies
Median

4

Range

2-13

Ibrutinib as most recent prior therapy*

30 (91)

Duration of prior ibrutinib treatment, mo

Characterization of ibrutinib-related AEs at
study entry
Thirty-three patients reported 61 ibrutinib-related AEs that led to
intolerance at study entry; a patient could have had .1 AE
leading to ibrutinib intolerance. Patients reported a median of
1 ibrutinib-related AE (range, 1-4 AEs), most commonly rash
(24%), arthralgia (18%), diarrhea (15%), fatigue (12%), and
hemorrhage (12%; Figure 2). Ibrutinib-related AEs were grade 1, 2,
3, or 4 in 9%, 36%, 42%, and 6% of patients, respectively; 6% were
of unknown grade. The most common grade $3 AEs on ibrutinib that
led to intolerance were rash, arthralgia, and diarrhea (6% each).
Other AEs experienced during prior ibrutinib treatment and resulting
in intolerance included 2 cases of atrial fibrillation and 10 bleedingrelated AEs (hemorrhage, n 5 4; hematoma, n 5 2; and conjunctival
hemorrhage, contusion, ecchymosis, and subdural hematoma,
n 5 1 each).

Patient disposition
After a median of 19.0 months (range, 0.7-30.6 months) on
treatment, 23 patients (70%) remained on acalabrutinib therapy
and 10 (30%) discontinued (Figure 1). Four patients (12%)
discontinued because of progressive disease (Richter transformation, n 5 2), and 3 (9%) discontinued because of AEs (metastatic
endometrial cancer, n 5 1; hemorrhagic stroke, n 5 1 [event
occurred on study day 17 in a patient with extensive prior history of
thrombocytopenia in the setting of grade 3 thrombocytopenia]; and
Aspergillosis infection, n 5 1 [patient received 2 months of ibrutinib
treatment and 2.7 months of acalabrutinib treatment]). Additionally,
3 patients (9%) discontinued because of physician decision
(concurrent hemophilia that was present at baseline, n 5 1;
increased BTK resistance, n 5 1 [patient discontinued before
meeting IWCLL criteria for disease progression]; and CLL central
nervous system involvement, n 5 1). Two deaths were reported
during the study period, 1 resulting from hemorrhagic stroke and
1 resulting from disseminated Aspergillosis infection, both noted
above.
There were no acalabrutinib dose reductions because of AEs. Nine
patients (27%) receiving acalabrutinib had dose holds (defined as
missing dose for $7 consecutive days; because of AE, n 5 1
[metastatic endometrial cancer]; delayed first dose, n 5 1; patient
error, n 5 2; procedure, n 5 3; discrepant dosing record, n 5 1;
1556
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Median

12

Range

1-62

Time from ibrutinib end to acalabrutinib start, d
Median

47

Range

3-331

Baseline cytopenias
ANC #1.5 3 109/L

4 (12)

Hemoglobin #11.0 g/dL

9 (27)

Platelets #100 3 10 /L

13 (39)

9

Genomic status
del(11q)

7/32 (22)

del(17p)

12/32 (38)

del(13q)

21/27 (78)

TP53 mutation

8/27 (30)

NOTCH1 mutation

2/27 (7)

SF3B1 mutation

4/27 (15)

Unmutated IGHV

25/31 (81)

ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group.
*Other most recent prior therapies: venetoclax, n 5 1; methylprednisolone with rituximab,
n 5 1; investigational drug (TG02), n 5 1.

steroid taper, n 5 1; and unknown, n 5 2), and 2 patients (6%) had
a temporary dose reduction (defined as taking lower dose level for
$3 consecutive days; because of patient error and surgery, n 5 1
each). Notably, only 1 of the 9 patients who had a dose hold
showed disease progression on acalabrutinib.

Safety
Events with acalabrutinib. The most common AEs of any
grade in the 33 patients irrespective of attribution were diarrhea
(58%), headache (39%), and cough (33%; Table 2); all of these
AEs were grade 1 or 2. Grade $3 AEs that occurred in .1 patient
each (.3%) included neutropenia (n 5 4; 12%); thrombocytopenia
(n 5 3; 9%); and pneumonia, anemia, and hypertension (n 5 2
each; 6%). Fifteen patients (45%) experienced serious AEs, most
commonly infections (n 5 10 patients, including 2 with pneumonia);
all other serious AEs occurred in 1 patient each, except for pyrexia
(n 5 2 patients).
14 MAY 2019 x VOLUME 3, NUMBER 9

Did Not Recur*

Recurrent

4

Grade

3

2

0

Neutropenia
Subdural hematoma
Rash
Arthralgia
Arthralgia
Diarrhea
Fatigue
Hemorrhage
Conjunctival hemorrhage
Febrile neutropenia
Organizing pneumonia
Paraneoplastic arthritis
Ventricular extrasystoles
Rash
Rash
Arthralgia
Arthralgia
Myalgia
Atrial fibrillation
Erythema nodosum
Erythema nodosum
Hematoma
Abdominal pain
Arthritis
Dermatitis acneiform
Dermatitis bullous
Pneumonitis
Vision blurred
Rash
Arthralgia
Diarrhea
Hemorrhage
Hemorrhage
Hematoma
Blood blister
Facial pain
Increased tendency to bruise
Nausea
Rash
Diarrhea
Myalgia
Panniculitis
Arthralgia
Diarrhea
Ecchymosis
Fatigue
Atrial fibrillation
Fatigue
Muscle spasms
Myalgia
Peripheral edema
Rash
Rash
Contusion
Fatigue

1

Figure 2. Change in ibrutinib-related AEs during acalabrutinib treatment. *An additional 6 events of unknown grade (rash, diarrhea, hemorrhage, decreased appetite,
dyspnea, and weight decreased) did not recur.

During acalabrutinib treatment, 2 atrial fibrillation events (grade 2,
n 5 1; grade 3, n 5 1) and 1 atrial flutter event (grade 3, n 5 1) were
reported. The grade 2 atrial fibrillation event occurred in a patient with a
medical history of paroxysmal atrial fibrillation (related to prior ibrutinib
treatment) who had discontinued an antiarrhythmic medication 15 days
before the event. One case each of new grade 3 atrial fibrillation and
grade 3 atrial flutter occurred in the setting of an acute pulmonary

infection. No dose modification was required. Four other patients with
a medical history of atrial fibrillation or flutter did not experience
recurrence during acalabrutinib treatment. One case of de novo
supraventricular tachycardia (grade 2) occurred, requiring
hospitalization; the patient remained on study drug.
Twenty-two patients experienced bleeding events; all but 1 were
grade 1 or 2 events. Bleeding AEs that occurred in .1 patient each

Table 2. AEs experienced during acalabrutinib treatment (‡15% any grade) for all treated patients (N 5 33)
n (%)
AE

Any grade

Grade 1

Grade 2

Grade 3

Diarrhea

19 (58)

15 (45)

4 (12)

0

Grade 4
0

Headache

13 (39)

9 (27)

4 (12)

0

0

Cough

11 (33)

6 (18)

5 (15)

0

0

Weight increased

10 (30)

6 (18)

3 (9)

1 (3)

0

Nausea

9 (27)

6 (18)

2 (6)

1 (3)

0

Contusion

8 (24)

5 (15)

3 (9)

0

0

Upper respiratory tract infection

8 (24)

2 (6)

5 (15)

1 (3)

0

Arthralgia

7 (21)

6 (18)

1 (3)

0

0

Pyrexia

7 (21)

5 (15)

1 (3)

1 (3)

0

Vomiting

7 (21)

5 (15)

2 (6)

0

0

Fatigue

6 (18)

3 (9)

3 (9)

0

0

Myalgia

6 (18)

2 (6)

3 (9)

0

0

Rash

6 (18)

5 (15)

1 (3)

0

0

Constipation

5 (15)

4 (12)

1 (3)

0

0

Dizziness

5 (15)

3 (9)

2 (6)

0

0

Ecchymosis

5 (15)

4 (12)

1 (3)

0

0

Fall

5 (15)

3 (9)

2 (6)

0

0

Noncardiac chest pain

5 (15)

3 (9)

1 (3)

1 (3)

0
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Table 3. Investigator-assessed responses in treated patients (N 5 33)
n (%)

CR (bone marrow confirmed)

1 (3.0)

PR

19 (57.6)

PRL

5 (15.2)

Stable disease

6 (18.2)

ORR (‡ PR)

20 (60.6)

95% CI*

42.1-77.1

ORR (‡ PRL)

25 (75.8)

95% CI*

57.7-88.9

1.0

Progression-free survival
(proportion of patients)

Best response

0.8
0.6
0.4
0.2
Censored

0.0
0

2

4

6

8 10 12 14 16 18 20 22 24 26 28 30 32 34 36

Months from initiation of study treatment

*95% exact binomial confidence interval (CI).

At Risk 33 30 29 29 27 26 24 23 22 15 9

9

5

2

1

1

0

Figure 3. PFS.

(.3%) included contusion (n 5 8; 24%); ecchymosis (n 5 5;
15%); and epistaxis, hematuria, increased tendency to bruise,
petechiae, and rectal hemorrhage (n 5 2 each; 6%). Two events
were considered major bleeding events (defined as grade $3,
serious, or affecting the central nervous system): a cerebral
microhemorrhage (grade 2) in a patient with a prior history of
stroke and hypertension and a gastric hemorrhage (grade 3) in
the setting of thrombocytopenia and immune thrombocytopenic
purpura.
Five patients (15%) experienced events of hypertension, 3 of
which were grade 3. Of these 5 patients, 3 had a medical history of
hypertension, and 2 of these 3 patients had grade 3 hypertension
AEs on study.
Ibrutinib-related AE recurrence. During treatment with
acalabrutinib, 21 patients (64%) did not experience a recurrence of
AEs that led to ibrutinib intolerance; 12 (36%) had a recurrence of
$1 event. Of the 61 ibrutinib-related AEs that led to intolerance
among the 33 patients, 44 events (72%) did not recur, and 17
ibrutinib-related AEs (28%) recurred during acalabrutinib treatment,
including 8 (13%) that recurred at a lower grade and 7 (11%) that
recurred at the same grade. Of the 9 recurrent AEs that were
grade $2 during ibrutinib treatment, 8 (89%) recurred with
decreased severity during acalabrutinib treatment (Figure 2). One
grade 2 event and 6 of the 8 grade 1 events recurred with the
same severity. Two AEs were grade 1 during ibrutinib treatment
and then recurred at grade 2 during acalabrutinib treatment
(contusion and fatigue). Fatigue, rash, myalgia, and diarrhea each
recurred in .1 patient.
As described, the most common ibrutinib-related events reported
at baseline were rash, arthralgia, diarrhea, fatigue, and hemorrhage.
Of the 8 rash events, 5 did not recur, 1 recurred at a lower grade,
and 2 recurred at the same grade (Figure 2). Of the 6 arthralgia
events, 5 did not recur and 1 recurred at a lower grade. Of the 5
diarrhea events, 3 did not recur and 2 recurred at a lower grade.
Of the 4 fatigue events, 1 did not recur, 1 recurred at a lower
grade, 1 recurred at the same grade, and 1 recurred at a higher grade.
None of the 4 hemorrhage events recurred.
Of the 10 bleeding events that occurred during ibrutinib treatment
and resulted in intolerance, 2 (contusion and ecchymosis) recurred
during acalabrutinib treatment.
Median follow-up of the 12 patients with recurrent AEs was
18.5 months (range, 0.6-26.9 months). Most ibrutinib-related
1558
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AEs recurred early with acalabrutinib treatment, with a median
time to onset of 14 days (range, 4-337 days). Of the 12 patients
with recurrent AEs, 8 continued acalabrutinib treatment and 4
discontinued because of disease progression (n 5 2 [Richter
transformation, n 5 1]) or an AE (n 5 2 [stroke and endometrial
cancer]). No patients discontinued acalabrutinib because of
recurrent ibrutinib-related AEs.

Efficacy
Investigator-assessed responses are listed in Table 3. The ORR
(PRL or better) was 76%, with 1 CR, 19 PRs, and 5 PRLs. All
patients achieved at least stable disease. Of 6 patients with
stable disease as best response, 2 had no detectable lymphadenopathy on imaging at baseline. Of 6 patients who did not
meet the conventional IWCLL criteria for treatment, 1 never
received acalabrutinib, 1 had a CR, 1 had a PR, and 3 had stable
disease relative to baseline disease. Notably, 2 of the 33 treated
patients did not have a response assessment; 1 patient received
5 days of acalabrutinib treatment before physician decision to
discontinue because of concurrent hemophilia, and 1 patient
received 18 days of acalabrutinib treatment before treatment
was terminated for grade 5 stroke. Median time to PRL or better
was 1.9 months (range, 1.6-19.2 months). Among the 25
responders, median DOR (PRL or better) was not reached;
82% (95% CI, 59%-93%) of the 25 responders had a DOR
$12 months. Median PFS was not reached; 1-year PFS was
83.4% (95% CI, 64.5%-92.7%); 2-year PFS was 75.0% (95% CI,
54.2%-87.4%; Figure 3).
Across risk-stratification subgroups, investigator-assessed
overall responses were similar. In patients with del(11)(q22.3),
del(17)(p13.1), and unmutated IGHV (n 5 7, 12, and 25,
respectively), ORRs (PRL or better) were 86% (95% CI,
42%-100%), 67% (95% CI, 35%-90%), and 80% (95% CI,
59%-93%), respectively. In patients with $4 prior therapies
(n 5 20), ORR was 65% (95% CI, 41%-85%) and 2-year
PFS was 76% (95% CI, 48%-91%). Median follow-up was
19.0 months (range, 12.7-28.9 months) for patients with
del(11)(q22.3), 13.6 months (range, 0.7-30.6 months) for
patients with del(17)(p13.1), 19.0 months (range, 0.7-28.9 months)
for patients with unmutated IGHV, and 17.0 months (range,
0.7-30.6 months) for patients with $4 prior therapies. Median
PFS was not reached in any of these subgroups. Three patients
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Figure 4. Acalabrutinib pharmacodynamics in ibrutinib-intolerant patients. (A) BTK occupancy for ibrutinib-intolerant patients with day-1 (D1) predose (Pre)
signal/noise ratio $5 (n 5 4 patients excluded for this reason). For the box plots, the horizontal line in the center of the box shows the median, and the upper and lower edges
of the box show the 25th and 75th percentiles, respectively. The I bars (whiskers) represent 1.53 the interquartile range, with symbols showing outliers according to the Tukey
method. (B) BCR-induced BTK phosphorylation (p) shown as fold over D1 predose plus exogenous acalabrutinib control. Filtered on D1 predose fold change .1.5 (n 5 15
patients excluded for this reason; n 5 2 patients had insufficient cells to perform the assay). Significance was determined using a paired, 2-tailed, parametric Student t test
comparing time points with D1 predose. ***P , .001, ****P , .0001. C, cycle; Post, postdose; SD, standard deviation.

had other therapies between ibrutinib and acalabrutinib: there
were no posttreatment response assessments for the patients
who received venetoclax (n 5 1) or TG02 (n 5 1); the best
response was stable disease for the patient who received
methylprednisolone with rituximab (n 5 1).

Pharmacodynamics
The pharmacodynamic response to acalabrutinib in this cohort
is shown in Figure 4. Median BTK occupancy was 98% 4 hours
postdose and remained high (.94%) over the treatment interval
at all points tested (Figure 4A). Phosphorylation of BTK at the
tyrosine 223 residue in response to ex vivo BCR stimulation was
almost fully inhibited 4 hours postdose and remained at or below
baseline at all points tested (P , .001; Figure 4B).

Genomic analysis
Where sufficient PBMCs were available from baseline non–
B cell–selected blood collections (n 5 30), genomic analysis
confirmed the absence of BTK C481S and known phospholipase C-g2 (PLCg2) mutations with a .5% allelic fraction (data
not shown).31,34

Discussion
Ibrutinib provides an oral therapeutic option for both newly
diagnosed and relapsed/refractory patients with CLL. However,
treatment-emergent AEs, such as atrial fibrillation, arthralgias, rash,
diarrhea, and bleeding, lead to discontinuation in 9% to 23% of
patients,6-14 and this poor tolerability may impede clinical benefit
for patients. These treatment-emergent AEs are thought to be
mediated in part by the binding of ibrutinib to non-BTK targets.
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Acalabrutinib is a more selective BTK inhibitor,16 developed to
minimize off-target kinase interactions while potently inhibiting BTK.
Results from this study demonstrate that patients with CLL who
discontinued ibrutinib treatment because of intolerance were able
to tolerate acalabrutinib treatment and achieve promising disease
control.
Patients in this study were distinctive vs patients enrolled in prior
studies with acalabrutinib or other BTK inhibitors; all were intolerant
to ibrutinib. Of the 33 patients who could not tolerate ibrutinib, only
3 discontinued acalabrutinib because of AEs. Acalabrutinib also
demonstrated a favorable safety profile similar to that observed
with acalabrutinib in BTK inhibitor–naive patients17,31; common
AEs were low grade (grade #2), and no patients required dose
modifications because of AEs. Of the AEs that led to ibrutinib
intolerance, 72% did not recur and 13% recurred at a lower
grade with acalabrutinib treatment. Moreover, 70% of patients
remained on acalabrutinib treatment at a median follow-up of
19 months. Generally, the safety profile of acalabrutinib in
this ibrutinib-intolerant population was consistent with previous
reports of acalabrutinib in BTK inhibitor–naive patients with
relapsed or refractory CLL,17,31 demonstrating that acalabrutinib
tolerability is not decreased in the subset of patients who are
intolerant to ibrutinib. Some AEs associated with ibrutinib
treatment (including atrial fibrillation and bleeding) were also
observed during acalabrutinib treatment; however, the degree
to which these events were associated with BTK signaling
is unclear. An ongoing, head-to-head study in patients with
high-risk CLL (registered at www.clinicaltrials.gov as #NCT02477696)
is under way to delineate the safety profiles of these 2 BTK
inhibitors.
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Sustained disease control likely requires prolonged, continuous
BTK inhibition. Patients who cannot continue ibrutinib treatment
because of intolerance and who have not progressed while on
therapy may benefit from treatment with acalabrutinib, an
alternative and more selective BTK inhibitor; in such ibrutinibintolerant patients, acalabrutinib may provide continued disease
control with improved tolerability. In this relapsed population, all
tested patients were negative for known BTK/PLCg2 resistance
mutations, including C481S, at a sensitivity of 5%. This finding is
consistent with the absence of clinical progression while on prior
ibrutinib treatment and the high response rate with acalabrutinib
treatment. In the current study, patients achieved an ORR
of 76% (Table 3), with response measured relative to clinical
parameters at the start of acalabrutinib treatment. Disease
progression or an indication for treatment was not required for
study entry, and it is possible that the 76% response rate
observed may be higher than expected for patients with more
advanced disease. Also, patients who most recently received
prior ibrutinib treatment may have still been responding to
ibrutinib. However, differing lengths of prior ibrutinib treatment
and time between BTK inhibitor therapies complicate the
interpretation of these responses.
Patients in this study cohort showed near-complete BTK
occupancy with acalabrutinib treatment over the treatment
interval (Figure 4), comparable with results from a previously
studied population of BTK inhibitor–naive patients with relapsed
or refractory CLL who received acalabrutinib.17 High BTK occupancy
was accompanied by inhibition of BCR-mediated BTK phosphorylation, demonstrating the expected pharmacological activity for
acalabrutinib. The drop of BTK phosphorylation below baseline
levels may in part result from a decrease in total BTK protein, as
previously reported.37
Limitations of this study include the retrospective collection of
ibrutinib-related AEs, which were based on patient or physician
recall and judgment. Standardized objective criteria to define ibrutinib intolerance would have allowed a clearer interpretation of the safety and efficacy of acalabrutinib in this
population. However, of 61 ibrutinib-related AEs that led to
intolerance, 85% did not recur or recurred at a lower grade
with acalabrutinib treatment, including all grade $3 events
that led to ibrutinib discontinuation. It is possible that some
patients in this retrospective study would have tolerated
ibrutinib if rechallenged at a lower dose; the availability of a
more selective BTK inhibitor may have prompted switching
to acalabrutinib instead of optimizing ibrutinib therapy.
Also, because follow-up of acalabrutinib-treated patients was
limited, it is possible that patients may develop intolerance
with continued acalabrutinib treatment. Additionally, central
laboratory assessment of BTK and PLCg2 mutation had a
sensitivity of 5%, which likely did not identify patients with low
levels of resistance to ibrutinib.
Overall, these data show that acalabrutinib is tolerated in most
patients with CLL who develop ibrutinib intolerance, with demonstrated clinical benefit. The efficacy and safety of acalabrutinib in
patients with relapsed or refractory CLL who are intolerant to
ibrutinib therapy are being further evaluated in an ongoing phase 2
study in which intolerance is more objectively defined (registered
at www.clinicaltrials.gov as #NCT02717611).
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